Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-NIVESTYM filgrastim-aafi SUBCUT 10 SYRINGE 300 MCG PFS 0.5 ML BY Pfizer

RX786459Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Rx Item-NIVESTYM filgrastim-aafi SUBCUT 10 SYRINGE 300 MCG PFS 0.5 ML BY Pfizer

$2628.00$2502.86

NDC No.69029110 00069-0291-10 00069-291-10 0006929110 00069029110 UPC/GTIN No.3-00690-29110-9 300690-291109 300690291109 MPN No.029110 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist, & Pharmacist, PA, Physical Therapist, Podiatrist, Research Co., Uni., VA, Vet & Wholesalers In Scope Of their Practice Can Order Rx Item.

Have a question?

For: Neutropenia Associated with Chemotherapy, Febrile Neutropenia

Nivestym (filgrastim-aafi) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.

FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to NeupogenInjection: Single-dose vials containing 300 mcg/mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution. Dispensing packs of 10 vials (NDC 0069-0293-10).

Injection: Single-dose vials containing 480 mcg/1.6 mL (300 mcg/mL) of a sterile, clear, colorless, preservative-free filgrastim-aafi solution. Dispensing packs of 10 vials (NDC 0069-0294-10).

Prefilled Syringes

Injection: Single-dose prefilled syringe with BD UltraSafe Plus� Passive Needle Guard, containing 300 mcg/0.5 mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution.

Pack of 1 prefilled syringe (NDC 0069-0291-01).
Pack of 10 prefilled syringes (NDC 0069-0291-10).

Injection: Single-dose, prefilled syringe with BD UltraSafe Plus� Passive Needle Guard, containing 480 mcg/0.8 mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution.

Pack of 1 prefilled syringe (NDC 0069-0292-01).
Pack of 10 prefilled syringes (NDC 0069-0292-10).

The NIVESTYM syringe plunger stopper and needle cover are not made with natural rubber latex [see Dosage and Administration (2.5)].

Storage

Store NIVESTYM in the refrigerator at 2� to 8�C (36� to 46�F) in the original carton to protect from light. Do not leave NIVESTYM in direct sunlight. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard NIVESTYM if frozen more than once. Avoid shaking. Transport via a pneumatic tube has not been studied. These highlights do not include all the information needed to use NIVESTYM safely and effectively. See full prescribing information for NIVESTYM.

NIVESTYM� (filgrastim-aafi) injection, for subcutaneous or intravenous use
Initial U.S. Approval: 2018
NIVESTYM (filgrastim-aafi) is biosimilar* to NEUPOGEN (filgrastim).
INDICATIONS AND USAGE

NIVESTYM is a leukocyte growth factor indicated to

Decrease the incidence of infection� as manifested by febrile neutropenia� in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. (1.1)
Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). (1.2)
Reduce the duration of neutropenia and neutropenia-related clinical sequelae� e.g.� febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). (1.3)
Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. (1.4)
Reduce the incidence and duration of sequelae of severe neutropenia (e.g.� fever� infections� oropharyngeal ulcers) in symptomatic patients with congenital neutropenia� cyclic neutropenia� or idiopathic neutropenia. (1.5)

DOSAGE AND ADMINISTRATION

Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML.
Recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion. See Full Prescribing Information for recommended dosage adjustments and timing of administration. (2.1)
Patients with cancer undergoing bone marrow transplantation.
10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. See Full Prescribing Information for recommended dosage adjustments and timing of administration. (2.2)
Patients undergoing autologous peripheral blood progenitor cell collection and therapy.
10 mcg/kg/day subcutaneous injection. (2.3)
Administer for at least 4 days before first leukapheresis procedure and continue until last leukapheresis. (2.3)
Patients with congenital neutropenia.
Recommended starting dose is 6 mcg/kg subcutaneous injection twice daily. (2.4)
Patients with cyclic or idiopathic neutropenia.
Recommended starting dose is 5 mcg/kg subcutaneous injection daily. (2.4)
Direct administration of less than 0.3 mL (180 mcg) using NIVESTYM prefilled syringe is not recommended due to potential for dosing errors. (2.5)

DOSAGE FORMS AND STRENGTHS

Vial

Injection: 300 mcg/mL in a single-dose vial (3)
Injection: 480 mcg/1.6 mL in a single-dose vial (3)

Prefilled Syringe

Injection: 300 mcg/0.5 mL in a single-dose prefilled syringe (3)
Injection: 480 mcg/0.8 mL in a single-dose prefilled syringe (3)

CONTRAINDICATIONS

Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products. (4)
WARNINGS AND PRECAUTIONS

Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1)
Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS.
Discontinue NIVESTYM in patients with ARDS. (5.2)
Serious allergic reactions, including anaphylaxis: Permanently discontinue NIVESTYM in patients with serious allergic reactions. (5.3)
Fatal sickle cell crises: Have occurred. (5.4)
Glomerulonephritis: Evaluate and consider dose-reduction or interruption of NIVESTYM if causality is likely. (5.5)

ADVERSE REACTIONS

Most common adverse reactions in patients:

With nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs (? 5% difference in incidence compared to placebo) are pyrexia, pain, rash, cough, and dyspnea. (6.1)
With AML (? 2% difference in incidence) are pain, epistaxis and rash. (6.1)
With nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT (? 5% difference in incidence) is rash. (6.1)
Undergoing peripheral blood progenitor cell mobilization and collection (? 5% incidence) are bone pain, pyrexia and headache. (6.1)
With severe chronic neutropenia (SCN) (? 5% difference in incidence) are pain, anemia, epistaxis, diarrhea, hypoesthesia and alopecia. (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

*
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.
Biosimilarity of NIVESTYM has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

Revised: 7/2018

RX786459
Rx Item-NIVESTYM filgrastim-aafi SUBCUT
RX786459

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
Rx Item-NIVESTYM filgrastim-aafi SUBCUT
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
AmericanPharmaWholesale.com
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop